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Abstract
Over expression of receptor tyrosine kinases is responsible for the development of a wide variety
of malignancies. Termination of growth factor signaling is primarily determined by the down
regulation of active growth factor/receptor complexes. In recent years, considerable insight has
been gained in the endocytosis and degradation of growth factor receptors. A crucial player in this
process is the EGFR Protein tyrosine kinase Substrate #15, or Eps15. This protein functions as a
scaffolding adaptor protein and is involved both in secretion and endocytosis. Eps15 has been
shown to bind to AP-1 and AP-2 complexes, to bind to inositol lipids and to several other proteins
involved in the regulation of intracellular trafficking. In addition, Eps15 has been detected in the
nucleus of mammalian cells. Activation of growth factor receptors induces tyrosine
phosphorylation and mono-ubiquitination of Eps15. The role of these post translational
modifications of Eps15 is still a mystery. It is proposed that Eps15 and its family members Eps15R
and Eps15b are involved in the regulation of membrane morphology, which is required for
intracellular vesicle formation and trafficking.
Introduction
Receptor tyrosine kinases (RTK) are a large family of sign-
aling proteins involved in a large number of human dis-
eases. They all have a similar composition: an extracellular
domain that binds to a growth factor, a trans-membrane
domain, an intracellular tyrosine kinase domain and a
stretch of tyrosine residues that serves as substrates for the
kinase. Binding of the growth factor results in kinase acti-
vation and consequently in the trans-phosphorylation of
the receptor, as well as of various effector molecules
resulting in the stimulation of a large number of signaling
cascades. One of the most studied RTKs is the epidermal
growth factor (EGF) receptor (EGFR or ErbB1), which
belongs to a family of four related receptor tyrosine
kinases (ErbB1-4 or Her1-4)). EGFR and its family mem-
bers are strongly implicated in the development and pro-
gression of different human tumors, including breast-,
lung-, prostate-, colorectal-, head and neck- and brain
tumors [1]. These cancers are often correlated with recep-
tor over-expression and/or mutations in the receptor tyro-
sine kinase, frequently associated with poor prognosis for
patients [2].
Attenuation of RTK signaling is governed by several mech-
anisms. At the receptor level, tyrosine phosphatases
reduce the number of phosphorylated tyrosine residues.
At the cellular level, inhibition of signaling is accom-
plished by receptor desensitization or down regulation.
This process involves the internalization of active ligand/
receptor complexes and subsequent trafficking to lyso-
somes, where receptors are degraded [3]. Ubiquitination
of the RTKs is considered as an important step both in the
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recruitment of receptors into coated pits and in the sorting
process in the early endosome [4,5]. Aberrant expression
of regulators of endocytosis and consequently of receptor
down regulation is strongly related to the development of
many different cancers [6]. For instance, abolishment of
the ubiquitination of EGFR by mutations in the involved
E3 ligase, c-Cbl, has been found to result in oncogenic
transformation [7]. The recruitment of active, ubiquiti-
nated receptors into coated pits is an example of a process
in which many different proteins with multiple pro-
tein:protein interactions are involved. One of the major
players in this process is the scaffolding protein Eps15.
A dual function for Eps15
The EGFR Protein tyrosine kinase Substrate # 15 (Eps15)
was originally identified in 1993 in a pool of proteins that
became phosphorylated after stimulation of cells with
EGF [8]. In the same period, Eps15 was identified as a
binding partner of -adaptin, a component of the AP-2
complex and part of clathrin-coated pits and vesicles [9].
A protein related to Eps15, Eps15R, was indentified as a
binding partner of the oncogenic variant of the adaptor
protein Crk (v-Crk) [10]. The v-Crk SH3 domain was
found to bind to a proline rich sequence present in the C-
terminal part of the protein (Fig. 1). The amino acid
sequence of Eps15R is 41% identical and 61% similar to
that of Eps15 [10]. Localization experiments using confo-
cal microscopy showed co-localization of Eps15 with -
adaptin and clathrin, but not with rab4 and rab5, indica-
tive for a localization in coated pits [11]. Similar results
were obtained for Eps15R [12]. Interestingly, electron
microscopy only revealed the presence of Eps15 at the rim
of the coated pit [13].
The localization of Eps15 in coated pits strongly suggested
the implication of Eps15 in the internalization of the
EGFR. Different experimental approaches have now con-
firmed this role. Microinjection of antibodies against
Eps15 were shown to inhibit the internalization of EGFR
and of the transferrin receptor [14]. More recently, knock-
down of both Eps15 and Eps15R showed a 40% inhibi-
tion of transferrin and EGF uptake indicating an
important role for Eps15 and Eps15R in clathrin-medi-
ated endocytosis [15]. Silencing of spartin, a binding part-
ner of Eps15, has been shown to result in aberrant
trafficking of the EGFR, which may underlie the pathogen-
Domain structure of the Eps15 proteins Figure 1
Domain structure of the Eps15 proteins. Different functional regions are indicated, green: Eps15 Homology or EH 
domains; light bleu: specific Eps15b region; dark blue: coiled-coil region; orange: binding site to -adaptin; light green: binding 
site for -adaptin; purple: proline rich motifs (prm); red: ubiquitin interacting motifs (UIM) and blue: nuclear export signal 
(NES). Y850 tyrosine phosphorylation site in Eps15. Although Eps15b has multiple DPF motif it binds poorly to -adaptin in 
vivo [29]. The sequences of the two UIMs are shown. Note the double serine and alanine motifs (in red) in the UIM2.
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esis of Troyer syndrome [16]. Troyer syndrome is a hered-
itary spastic paraplegia characterized by progressive
spasticity and muscle weakness in the lower limbs. Simi-
larly, binding of Eps15 with parkin has been shown to
affect EGFR trafficking and signaling, which may be
related to the development of Parkinson's disease [17].
In addition to the presence and role of Eps15 in the endo-
cytic system, Eps15 and especially Eps15R have also been
found in the nucleus [18]. Eps15, but not Eps15R con-
tains a leucine-rich, nuclear export signal (NES) at its very
C-terminus that keeps it out of the nucleus [19]. Import of
Eps15R into the nucleus is independent of a nuclear local-
ization signal (NLS) and requires binding to proteins like
Hrb (HIV-1 Rev-binding protein) or another endocytic
protein Epsin1 [20]. Regulation of the nuclear-cytoplas-
mic shuttling of Eps15 is not clear. Once in the nucleus,
Eps15 has been shown to act as positive modulator of
transcription in a GAL4-based transactivation assay, sug-
gesting a direct or indirect role for Eps15 in transcriptional
regulation [18]. Moreover, other endocytic proteins were
also found in the nucleus, including intersectin, Epsin1,
CALM, HIP1, Dab1/2 and -arrestins. The Eps15 binding
partner intersectin was shown to activate the Elk-1 tran-
scription factor [21]. These observations suggest a dual
function for endocytic proteins including the two Eps15
homologues: in membrane sorting during endocytosis
and in regulating gene expression in the nucleus. Their
exact role in the nucleus is, however, far from clear [22].
The Eps15 gene is located at chromosome 1 at chromo-
somal locus p31-p32, which displays a high rate of ran-
dom chromosomal abnormalities such as deletions in
oligodendroglioma and neuroblastoma, and transloca-
tions in myeloid and lymphoblastic leukemia [23].
Fusion of Eps15 to transcription factors has been found in
certain forms of acute myeloid leukemia (AML), where
Eps15 is fused to the mixed lineage leukemia gene (MLL)
[24-26]. The MLL gene, which is also referred to as HRX,
ALL1 or HTRX, encodes a transcription factor regulating
the expression of Hox genes. These downstream targets of
MLL encode transcription factors with critical roles in
both embryonic and hematopoietic differentiation [27].
Fusion of the MLL protein with Eps15 resulted in dimeri-
zation of the fusion protein, which was found to activate
this transcription factor [27]. The MLL-Eps15 fusion pro-
tein, also indicated as HRX-ALL-Eps15 fusion protein, was
found exclusively in the nucleus, while the wild type MLL
protein localized to both the cytoplasm and nucleus [28].
This suggests that the fusion to Eps15 induces both the
activation and translocation of the protein to the nucleus,
which may be responsible for the oncogenic potential of
this fusion protein and the development of leukemia.
In summary, Eps15 is functioning in the cytoplasm, where
it is involved in in the regulation of intracellular traffick-
ing. In addition, its presence in the nucleus suggests a role
for Eps15 in transcriptional regulation. To understand the
working mechanism of Eps15 in its diverse physiological
functions, a detailed analysis of its structure and molecu-
lar binding partners is required.
Modular structure of the Eps15 proteins
Eps15 appears to be a member of a small group of pro-
teins: Eps15, Eps15R and Eps15b. Both Eps15 and Eps15R
are organized into four different domains (fig. 1). Eps15b
lacks domain I, but contains a unique N-terminal stretch
of 32 amino acids (fig. 1) [29]. Domain I contains three
different Eps15 homology or EH domains, which were
originally described as protein:protein interaction mod-
ules [30]. The EH domain is present in a great variety of
endocytic proteins such as intersectin, -synergen, Reps1
and EH domain containing proteins (EHDs) ([31-33].
Structural analysis by NMR has shown that the EH
domains consist of two anti-parallel oriented EF hands
[34,35]. The EF hand is a helix-turn-helix motif with Ca2+
binding properties, consisting of two -helices linked by a
short  -strand. The EH domains of Eps15 have been
found to bind Ca2+ constitutively with high affinity. Phage
display analysis has identified the protein motif this
domain binds to, being composed of the three amino acid
motif asparagine, proline and Phenylalanine (NPF) for
the first two domains [36]. The third EH domain displays
a different specificity: FW containing motifs preferentially
bind to this domain. Proteins containing EH domains are
predominantly involved in intracellular trafficking, sug-
gesting a general role for EH domains in intracellular
transport. GST-pull downs and yeast-two hybrid searches
have yielded several different binding partners of the EH
domains of Eps15, including the endocytic proteins
Epsin1, STAM (EAST), Stonin2, Numb, synaptojanin and
others (see table 1). The EH1 and EH4 domain of EHD1
and the EH2 domain of Eps15 were found to interact with
phosphatidyl-inositol lipids [37]. NMR studies indicated
positively charged lysine residues as critical for the phos-
pho-inositide binding, and these residues are also present
at homologous positions in the Eps15-EH2 domain [37].
EHD proteins can induce membrane curvature in vitro and
are also localized to the tubular structures of endosomal
membranes [38,39]. Although the EHD1 is required for
recycling of transferrin receptors, their function in the
induction of membrane curvature in vivo remains to be
seen [39].
The second domain of the Eps15, Eps15R and Eps15b
consists of a coiled-coil region, which has the capacity to
dimerize (fig. 1). As a result, Eps15 has been found as par-
allel and anti-parallel dimers and tetramers [40]. Moreo-
ver, this region has been shown to interact with theCell Communication and Signaling 2009, 7:24 http://www.biosignaling.com/content/7/1/24
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endocytic protein intersectin [41]. Recently, co-precipita-
tion of Eps15 with the EGFR and c-Met receptor was
shown to depend on the coil-coiled region [42]. Whether
this interaction is direct or mediated by other proteins is
not known.
The third domain is characterized by the presence of sev-
eral DPF motifs. These motifs play a role in the association
with the appendage or ear of -adaptin, a component of
the AP-2 complex [43]. C-terminal from the AP-2 binding
site is a small motif present, which is responsible for a
direct binding to -adaptin, a component of the AP-1
complex ([44,45]. Remarkably, the DPF motifs have also
been shown to function as ligands for the EH domains
[46]. This enables the formation of larger networks of
Eps15, consisting of Eps15 dimers that are connected to
each other via DPF/EH interactions. The question arises
whether those complexes exist in vivo and whether their
interactions with inositol lipids would facilitate self-asso-
ciation of Eps15. Indications for the existence of stable
Eps15 structures were obtained using isolated membrane
sheets. Staining of such ventral membranes with anti-
Eps15 antibodies showed the typical coated pit pattern
and colocalization with clathrin and -adaptin [11]. After
extraction of both clathrin and -adaptin from the mem-
brane the typical Eps15 distribution was still present, sug-
gesting that Eps15 itself could form a stable structure.
Table 1: Eps15 binding partners
Binding partner Interacting domain Function Reference
-adaptin DPF-motif Endocytosis [64]
-adaptin Domain III secretion [44,45]
Crk PRMs Unknown [10]
Eps15/Eps15R EH domain Unknown [46]
Epsin EH domain Endocytosis/nucleus [51]
Grb2 PRMs Endocytosis [10,42]
Hrb EH domain Nucleus/endocytosis [77,78]
Hrs n.d. Sorting [74]
Intersectin Coiled-coil domain Endocytosis [41]
Numb EH domain Endocytosis [36]
Parkin UIM domains Mono-ubiquitination [17]
POB1 n.d. Endocytosis [79]
Phocein n.d. Trafficking [80]
Spartin n.d. Endocytosis [81]
STAM (EAST) n.d. Sorting [74]
Stonin2 EH domain Endocytosis [53]
Synaptojanin EH domain Endocytosis [82]
Ubiquilin/PLIC UIM1 Aggresome formation [49]
Ubiquitin UIM2 Ubiquitination/unknown [59,60]
n.d.: not determinedCell Communication and Signaling 2009, 7:24 http://www.biosignaling.com/content/7/1/24
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The fourth domain of Eps15 can be indicated as the regu-
latory domain, as it contains at position 850 the tyrosine
residue that becomes phosphorylated upon stimulation
of the cell with EGF and HGF (Hepatocyte Growth Factor)
[42,47]. Endocytosis of EGFR could be specifically inhib-
ited by over-expression of an Eps15 mutant lacking this
site [47]. Domain IV also contains two proline rich
domains (prm), which were found capable of binding to
the adaptor proteins Crk and Grb2 [10]; the latter was also
shown to co-immunoprecipitate with the c-Met receptor
[42]. The nuclear export signal is located at the very C-ter-
minus of Eps15 and Eps15b but is absent in Eps15R [19].
In this part of Eps15, two ubiquitin interacting motifs
(UIM) are present of which the UIM2 sequence overlaps
with the NES [48]. These UIMs indeed bind to (poly)ubiq-
uitinated proteins, but binding to proteins containing a
Ubiquitin like domain (Ubl) such as ubiquilin-1 or PLIC
has also been observed [49]. Interestingly, the UIM1
appears to have higher affinity for this Ubl domain than
for ubiquitin, while the reverse was observed for the
UIM2. Among the highly conserved residues in the UIM
domains are the serine (S) and alanine (A) residues (fig.
1). UIM domains adopt an -helical structure and the S
and A residues are located at one site of the -helix. The
Eps15-UIM2 has two serine and alanine residues that are
located opposite of each other in the -helix. This has lead
to the hypothesis that the UIM2 can actually bind to two
ubiquitin moieties at the same time [50]. This would
explain the higher affinity of this UIM for poly-ubiquiti-
nated proteins as compared to that of UIM1.
Eps15 binding partners
Essential for an understanding of the function of Eps15 is
the determination of the protein binding partners of this
molecule. An overview of all known binding partners of
Eps15 is given in Table 1. One of the first Eps15 binding
partners that has been discovered was Epsin1, which
binds directly with its NPF motif to the first two EH
domains [51] of Eps15. Besides the NPF motif, the Epsin
family of proteins contains a lipid-binding domain, the
ENTH domain. Elegant electron microscopy studies have
shown that binding of Epsin to the membrane induces a
bending of the membrane, an essential step in the invagi-
nation process of the membrane required for vesicle for-
mation [52].
Searches for Eps15 binding partners using yeast-two-
hybrid screens have yielded many interesting new targets,
for instance Numb and Stonin2 (Table 1). Both proteins
are involved in the process of receptor internalization:
Numb in the internalization of the Notch receptor while
Stonin-2 is involved in the internalization of the receptor
for transferrin, EGF and LDL [53-55]. Several other endo-
cytic proteins have been found to bind Eps15, including
Hrs, STAM, synaptojanin, POB1, - and -adaptin and
intersectin, all pointing towards the essential role of Eps15
in secretion and internalization processes (Table 1).
The two UIMs in Eps15 were found to bind to at least two
ubiquitin E3-ligases, Nedd4 and Parkin (see below). Inter-
estingly, the first UIM of Eps15 has also been found to
bind to the Ubl-domain of ubiquilin or PLIC. Colocaliza-
tion experiments demonstrated the presence of Eps15 and
ubiquilin in intracellular aggregates [49]. Subsequent
gene silencing experiments of Eps15 demonstrated that
the association of Eps15 with ubiquilin is involved in the
formation of aggresomes and possibly also in the removal
of these aggregates [56]. Involvement of ubiquilin in
autophagy was recently confirmed by studies from
N'Diaye and coworkers who demonstrated this role of
ubiquilin in autophagy-dependent cell survival during
nutrient starvation [57]. This suggests the possibility that
Eps15, as an endocytic protein, might also be involved in
autophagy, the cellular process that is involved in the deg-
radation of large protein aggregates. However, more
research is required to better understand the role of Eps15
in the removal of protein aggregates.
Post translational modifications of Eps15: 
phosphorylation and ubiquitination
Eps15 was initially found as a tyrosine kinase substrate of
the EGFR. Further research indicated that the tyrosine at
position 850 acts at the target tyrosine residue [47]. Over
expression of an Eps15 mutant lacking this site could spe-
cifically block the endocytosis of the EGFR, but not that of
the transferrin receptor [47]. The involvement of a phos-
phorylated tyrosine residue in the functioning of Eps15
suggest the binding to a phosphotyrosine binding pro-
tein, which may recruit Eps15 either to the receptor or to
the endocytic machinery. However, such proteins that
may contain an SH2 or PTB domain have not been iden-
tified as yet.
Stimulation of the cell with EGF results in a remarkable
shift in the molecular weight of Eps15 and Eps15R [8].
This modification was found to be the result of the conju-
gation of one ubiquitin moiety: Eps15 mono-ubiquitina-
tion [58]. Detailed mapping of the structural elements
present in Eps15 that are required for ubiquitination indi-
cated an essential role for the UIM motifs [59,60]. Subse-
quently, the hunt was on for the Eps15 E3-ligase(s) that
could both bind to the Eps15-UIMs and ubiquitinate the
protein. Two E3 ligases have so far been identified: Nedd4
and parkin, both acting via different mechanisms [17,61].
In yeast, the E3 ligase Rsp5 has been implicated in numer-
ous cellular functions including protein degradation and
endocytosis [62]. Nedd4 can be considered as the human
orthologue of Rsp5 and this ligase was previously found
on endocytic vesicles [62]. Dr. Polo and colleagues inves-Cell Communication and Signaling 2009, 7:24 http://www.biosignaling.com/content/7/1/24
Page 6 of 11
(page number not for citation purposes)
tigated whether Nedd4 could act as a possible E3-ligase
for Eps15 [59]. Over-expression of Nedd4 resulted in an
increased ubiquitination of Eps15. In addition, purified
Nedd4 could ubiquitinate Eps15 in an in vitro ubiquitina-
tion assay [61]. A pre-incubation of Nedd4 in the in vitro
ubiquitination mixture clearly enhanced the mono-ubiq-
uitination of Eps15. These elegant studies demonstrated
that Nedd4 is first self-ubiquitinated, which allows it to
bind the second UIM2 of Eps15. Subsequently, Eps15
becomes ubiquitinated by the action of Nedd4 (fig. 2). In
addition, the authors suggested that upon conjugation of
one single ubiquitin moiety to Eps15, this ubiquitin moi-
ety may bind to the UIM2 on the same molecule, resulting
in the release of the Nedd4 and prevention of poly-ubiq-
uitination of Eps15 [61].
Following the finding that UIM motifs can also interact
with ubiquitin like domains (Ubl), E3 ligases were
screened for possessing an Ubl domain. This yielded Par-
kin, an E3 ligase related to the development of Parkin-
son's disease [17]. It was shown that the Ubl domain of
parkin binds to the UIM motifs of Eps15, which interac-
tion is required for the mono-ubiquitination to occur (fig.
2). In this way, Eps15 was ubiquitinated in an in vitro
ubiquitination assay, and over-expression of parkin
resulted in an increase in mono-ubiquitination of Eps15.
Possibly, a similar competition between the conjugated
ubiquitin and parkin for binding to the UIM2 may be
responsible for the prevention of poly-ubiquitination of
Eps15.
Although both E3 ligases Nedd4 and parkin are clearly
ubiquitinating Eps15, many questions remain unan-
swered. For instance, Nedd4 and parkin are both mem-
bers of the two different classes of E3 ligases: Nedd4
contains a C-terminal catalytic HECT domain, short for
homologous to the carboxyl terminus of the E3 ligase E6-
AP, while parkin contains a RING domain, short for really
interesting new gene. It is currently unclear how EGF-
mediated signaling would stimulate this parkin/Eps15
association and consequently stimulate Eps15 mono-
ubiquitination. Woelk and coworkers have shown that
also other HECT domain E3 ligases are ubiquitinated, and
the question arises whether all these ubiquitinated ligases
can also bind to Eps15, and consequently mono-ubiquiti-
nate Eps15 [61]. Probably, other additional factors may
be involved to guarantee specificity in the binding of
Eps15 with these HECT domain E3 ligases.
The most intriguing question remains the function of
Eps15 ubiquitination. As over expression of parkin was
found to enhance Eps15 mono-ubiquitination considera-
bly, this offered the possibility to study the effect of Eps15
mono-ubiquitination on EGFR internalization. Parkin
over expression clearly inhibited the internalization and
degradation of the EGFR, while silencing of parkin clearly
stimulated endocytosis [17]. Consequently, EGF-medi-
ated signaling towards PKB/Akt was stimulated under par-
kin over expression conditions. These results suggested
that the mono-ubiquitination of Eps15 may result in a
functional inhibition possibly by the formation of an
intra-molecular binding whereby the attached ubiquitin
binds to the UIM2 of the same molecule. This intramo-
lecular binding may prevent binding to -adaptin and, as
a result inhibit recruitment of Eps15 to the coated pit,
which may cause the inhibition of EGFR endocytosis. A
similar mechanism has been demonstrated for the Cbl-
binding protein Sts2 using Förster Resonance Energy
Transfer (FRET) of fluorescent proteins fused to the N-
and C-terminus of Sts2 [63]. However, intramolecular
binding of attached ubiquitin to the UIM2 of Eps15 has
not been demonstrated as yet. Determination of the ubiq-
uitination sites in Eps15 would be required for this kind
of experiments and we are currently mapping these ubiq-
uitination sites.
Eps15 and intracellular trafficking
Initial observations indicated the direct binding of Eps15
to  -adaptin and the co-localization of Eps15 with -
adaptin and the heavy chain of clathrin in coated pits
Different mechanisms for Eps15 ubiquitination Figure 2
Different mechanisms for Eps15 ubiquitination. The 
E3 ligases Nedd4 and parkin ubiquitinate Eps15 by different 
mechanisms: Nedd4 needs to be ubiquitinated before binding 
to the Eps15-UIM can occur. Parkin contains a UBL domain 
which binds constitutively to the UIMs of Eps15. HECT and 
RING domains are indicated in their respective E3 ligases.
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[9,11,64]. Involvement of Eps15 in the internalization of
growth factor receptors has thus far been demonstrated
for the EGFR and for the c-Met receptor [42,47]. In both
cases, stimulation of the cell with ligand results in Eps15
phosphorylation and ubiquitination. Eps15 then associ-
ates with particular receptor in the plasma membrane
[42,65]. The colocalization with the EGFR could be pre-
vented by over-expression of the Eps15-UIM motifs while
the induced association with the c-Met receptor was pre-
vented by over expression of the coil-coiled domain of
Eps15 (domain II) [42,66]. Thus, binding of Eps15 to the
ubiquitinated EGFR probably occurs via interactions of
the Eps15-UIMs with the ubiquitin moieties present on
the intracellular domain of EGFR. A similar mechanism
has been reported for the internalization of the junction
protein occludin that becomes ubiquitinated and inter-
nalized after stimulation of the cell with VEGF [67]. The
interaction of Eps15 with the c-Met receptor is more com-
plex. Besides a possible direct interaction of the coil-coiled
domain with the cMet receptor, the adaptor protein Grb2
may contribute to this association: Grb2 could possibly
bind the c-Met receptor via its SH2 domain (recognizing
the phosphorylated receptor), while its SH3 domain inter-
acts with the prm in Eps15 (Fig. 1)[42].
Since Eps15 is constitutively associated with the coated
pit, the induced binding with the activated receptors
would result in the recruitment of these receptors into the
coated pit. This is in line with the observation that the
EGFR is endocytosed via clathrin-coated vesicles How-
ever, accumulating evidence suggests that the EGFR can
also be internalized via a less well defined, clathrin inde-
pendent (Ci) pathway [68]. This is based on the fact that
EGF internalization could not be completely abolished by
inhibition of the CCV pathway, nor by over-expression of
a dominant negative mutant of Eps15 or by silencing the
clathrin heavy chain [68]. The dominant negative Eps15
variant lacks the EH domains, which result in a sequestra-
tion of -adaptin and consequently in inhibition of CCV-
mediated internalization [69]. Internalization of EGFR
through the alternative pathway was linked to ubiquitina-
tion of the EGFR. Silencing of both Eps15 variants and
epsin1 was found to block this alternative pathway dem-
onstrating a role of these three proteins also in this clath-
rin-independent (Ci) internalization route (fig. 3) [68].
The function of Eps15 can best be described using a model
of EGFR internalization. Activation of the EGFR results in
cross-phosphorylation of tyrosine residues in the intracel-
lular domain, causing the binding of SH2 containing pro-
teins, such as Grb2 and the E3 ligase Cbl. As Grb2 also
binds via its SH3 domain to a proline-rich motif in Cbl, a
complex of EGFR/Grb2/Cbl is formed resulting in mono-
and poly-ubiquitination of the EGFR [68]. This is fol-
lowed by the UIM-dependent binding of Eps15 to the
EGFR, resulting in the recruitment of EGFR to the coated
pit (Fig. 3). In addition, Eps15 is binding via its EH
domains to Epsin1, which may also bind to the poly-
ubiquitinated EGFR via its UIM domains [70]. The lipid-
binding EH and ENTH domains of Eps15 and Epsin-1
induce bending of the membrane. Further recruitment of
these molecules to the pit consequently results in the fur-
ther bending of the clathrin coated pit. In addition, also
other binding partners of Eps15 are recruited to the pit
and stimulate the formation of the coated vesicle further.
Remarkably, after vesicle formation Eps15 seems to be
absent from the vesicular structures [71]. Eps15 might
equally well bind to the ubiquitinated EGFR in the Ci
route, and stimulate, together with epsin1, the bending of
the membrane (Fig. 3). Proteins mediating the Ci path-
way, such as adaptor proteins, have not been identified
yet, and are subject of further research. It should be noted,
however, that the described Eps15 mediated internaliza-
tion of the EGFR is not the only mechanism for EGFR
internalization. For instance, EGFR dimerization has also
been shown to be stimulate endocytosis [72]. Moreover,
removal of the ubiquitination sites from the intracellular
domain of the EGFR did not affect EGF internalization,
indicating that several different internalization mecha-
nism are acting synergistically in the internalization of
EGFR [73].
Another suggested function for the Eps15 family members
lays in the sorting process of EGFR that occurs at the mem-
brane of the early endosome [74]. In this organelle, active,
phosphorylated EGFRs are being separated from inactive
receptors, a process named sorting. Four different protein
complexes have been identified to be responsible for this,
indicated as endosomal sorting complex required for
transport or ESCRT complexes 0-, I, II, and III [75]. Ubiq-
uitination of EGFR again plays an essential role in this
process, which also involves the ubiquitin-binding pro-
teins Hrs and STAM. Together, they form a complex with
the ubiquitinated receptor at the membrane of the early
endosome (ESCRT-0)[74]. The Eps15 isoform, Eps15b,
binds preferentially to Hrs and is also localized to endo-
somes [29]. It was suggested that the Eps15b isoform
functions specifically in complexes involved in sorting at
the endosome, while Eps15 and Eps15R may function at
the plasma membrane. The sorting process at the early
endosome also involves the three other ESCRT complexes,
which mediate the invagination of receptor containing
vesicles into the endosome, resulting in the formation of
multi-vesicular bodies (MVB) (Fig. 3) [76]. As these MVBs
finally fuse with lysosomes, this pathway defines the deg-
radation of the active, phosphorylated, and ubiquitinated
EGFRs.
A very recent finding is that Eps15 also showed localiza-
tion at the Golgi complex [11]. This is in agreement withCell Communication and Signaling 2009, 7:24 http://www.biosignaling.com/content/7/1/24
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Possible role of the Eps15 proteins in intracellular trafficking of EGFR Figure 3
Possible role of the Eps15 proteins in intracellular trafficking of EGFR. EGFRs are partly present in caveolae and are 
released from these structures upon activation. Phosphorylated EGFRs become ubiquitinated by the action of Cbl and are 
trapped by Eps15 in either the clathrin-coated vesicle (CCV) route or clathrin-independent route (Ci). Eps15 is associated to 
the ubiquitinated EGFR via its UIMs and to -adaptin in the AP-2-complex in the CCV, and to a putative adaptor protein (?) at 
the clathrin independent pit. Eps15b is found at the early endosome (EE) in a tri-complex with STAM and Hrs bound to the 
clathrin-coated sheet. Inactive EGFRs are recycled back to the plasma membrane while active receptors are packed in multi 
vesicular vesicles (MVB) by the actions of the ESCRT-0, -I, -II, and -III complexes and degraded in lysosomes.
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observations that the appendage of the -adaptin subunit
of the Golgi localized AP-1 complex binds to and colocal-
izes with Eps15 [45]. During further studies, a 14 amino
acid motif was identified that is located immediately C-
terminally from the AP-2 binding site in domain III of
Eps15. The exit of secretory proteins was significantly
reduced by silencing of -adaptin or overexpression of an
Eps15 mutant lacking the particular AP-1 binding site
[44]. This AP-1 binding site is also present in Eps15R and
Eps15b, but data about a function of these Eps15 variants
in secretion are so far lacking.
Concluding remarks
Since its discovery in 1993, a function for Eps15 has been
described in different processes, one related to a nuclear
function and one related to intracellular trafficking. In
trafficking, Eps15 acts as an ubiquitin- or Ubl-binding
adaptor protein, a function mediated by the two UIMs in
the C-terminal part of the molecule. Other domains in
Eps15 are involved in the recruitment of different compo-
nents that are critical for trafficking, including - and -
adaptin, Epsin1, synaptojanin etc. In these processes,
Eps15 functions as a scaffolding protein that recruits and
concentrates those proteins and lipids that are required
for the process. Post-translational modifications as phos-
phorylation and mono-ubiquitination might regulate
Eps15 functioning, but molecular details of these proc-
esses are still unknown. Similarly, details about the func-
tion of Eps15b in the ESCRT-0 complex is not clear.
Imaging of the internalization processes at high resolu-
tion may help to understand the molecular details of these
processes in the future. The trafficking role of the Eps15
molecules includes clearly two aspects: they are bound to
membranes and the morphology of these membranes are
manipulated. This has also been described for EHD1, an
EH domain containing protein that induces tubulation of
the membrane [39]. This suggest a general role for Eps15
and its family members in controlling membrane mor-
phology during the process of intracellular trafficking.
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